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POINTS 
. "1. Allograft rejection is mediated primarily by the 
T cell in response to the presence of an antigen, which 
is processed by antigen-presenting cells (APC) and 
carried on the major histocompatibility complex 
(MHC) molecules to the T cell. 
The T-cell receptor (TCR), in conjunction with 
accessory molecules such as CD3, CD4, and CD8, 
interacts with the antigen fragment on the 
MHC molecule and produces the growth factor 
interleukin-2 (IL-2) to activate the T cell and 
stimulate proliferation of the T cell. 
During allograft rejection, cytokines attract various 
cells into rejecting allografts, stimulate the produc-
tion of antibodies, and produce inflammation. 
Effective immunosuppressive protocols combine 
multiple drugs targeted at different sites of the 
T-cell activation cascade. 
Corticosteroids block the early steps of T-cell 
activation; they are used in tapering doses during 
the induction and maintenance phases of immuno-
suppressive protocols and in high, brief doses for 
the reversal of acute rejection episodes. 
The backbone of immunosuppressive protocols 
are the calcineurin inhibitors cyclosporine and 
tacrolimus, which inhibit IL-2 production and 
T-cell activation and proliferation. 
Azathioprine and mycophenolate mofetil inhibit 
synthesis, thereby disrupting the cell cycle 
T-cell proliferation. 
S' lim Iro us blocks the cellular response to IL-2 and 
the progression of the cell cycle, inhibiting 
proliferation. 
globulin and monoclonal 
are potent cytotoxic compounds that 
rapid, profound, and prolonged T-cell deple-
.they are effectively used to reverse acute 
episodes or as induction therapy before 
'''l~;nl'n+°tion. 
~oncentration monitoring is necessary to 
. efficacy in preventing allograft rejection 
mlDimizing the potential for significant 
~ffects; monitoring aids in the management 
Interactions, particularly with cyclosporine, 
and sirolimus therapy. 
Advances in molecular biology and immunology have pro-
vided for greater understanding of the mechanisms involved 
in allograft rejection. Many of the key pathways of organ 
rejection are targeted by the growing armamentarium of 
immunosuppressive drugs available today. The vast array of 
immunosuppressive combinations has dramatically decreased 
the incidence of acute allograft rejection. However, very little 
ground has been gained with respect to the impact of 
chronic allograft rejection on long-term allograft survival. 
Furthermore, the relative nonselectivity of the current 
immunosuppressants with long-term use can lead to the 
development of malignancies and opportunistic infections. 
As we continue to explore different combinations of 
immunosuppressants and new immunosuppressive pathways, 
we will continue to grow in our comprehension of the 
immune system and come closer to true allograft acceptance. 
BASIC PRINCIPLES OF 
IMMUNOSUPPRESSION 
Optimal immunosuppression, as it relates to transplantation, 
is defined as the level of drug therapy that achieves graft 
acceptance with least suppression of systemic immunity. 
By optimizing immunosuppressive therapy, systemic toxicity 
(i.e., infection and malignancy) and other side effects can be 
minimized, albeit not entirely eliminated. Because monitoring 
of blood levels and titration of immunosuppression on this 
basis is possible with only a few agents, in practice, oversup-
pression or undersuppression almost invariably becomes 
apparent only in retrospect. Recently, monitoring of CD3+ 
cell counts has provided an alternative means of measuring 
the degree of immunosuppression. 
Current immunosuppression protocols typically use 
multiple drugs, each directed at a discrete site in the T-cell 
activation cascade.! Most immunosuppressive regimens 
combine drugs, often with differing modes of action and tox-
icities, allowing lower doses of each drug. Transplantation 
immunosuppression can be (1) pharmacologic, consisting of 
drugs such as corticosteroids, cytokine suppressive agents, and 
cell cycle inhibitors, or (2) biologic, consisting of monoclonal 
and polyclonal antilymphocyte antibodies and anticytokine 
receptor antibodies.2 
The combination of cyclosporine or tacrolimus with a 
corticosteroid forms the backbone of most maintenance 
immunosuppressive regimens being used today. An anti-
proliferative agent may also be added. In general, the early 
postoperative period calls for the greatest degree of 
immunosuppression. As time goes on, many patients can 
maintain graft function with smaller doses of immuno-
suppressive agents. 
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If acute cellular rejection occurs, it is common to treat 
with a brief course of high-dose corticosteroid therapy, anti-
lymphocyte antibodies, or both. Generally, high doses of a 
corticosteroid are used initially to reverse the acute attack on 
the allograft. Antilymphocyte antibody therapy with mono-
clonal or polyclonal antibodies is used for more severe 
rejection or if corticosteroid therapy fails. 
Induction therapy, also called prophylactic therapy, refers 
to the use of antilymphocyte antibodies immediately after 
transplantation. This practice is based on the theory that 
early incapacitation of the immune system may reduce the 
likelihood of subsequent rejection. Claimed benefits are 
delayed onset of acute rejection, fewer episodes of rejection, 
and no significant increase in infectious complications.3,4 
The related concept of sequential therapy was introduced in 
response to the significant renal toxicity of cyclosporine 
observed in recipients of liver, heart, and kidney transplants. 
The practice is to use antibody therapy for the first 1 to 2 weeks 
after transplantation-the period in which renal injury is 
most likely to occur from a variety of insults. Cyclosporine 
therapy is not used during this period but is started later. 
The impact of this strategy on long-term renal function is 
much less clear. 
This early intensification of immunosuppression is not 
universally accepted. Some experts voice concern because of 
the well-known association between antilymphocyte antibody 
therapy (and immunosuppression in general) and infection 
and malignancy.5,6 Others describe no benefit, greater 
expense,? or the successful use of regimens that avoid induc-
tion altogether.8 Intermediate strategies involve the use of 
induction only in high-risk patients or the use of just one dose 
of an antilymphocyte agent, followed by early evaluation of 
renal function. 
Although some patients can tolerate complete withdrawal 
of immunosuppressive therapy without exhibiting rejection,3 
it is best done as a protocol-based strategy with patients 
under strict supervision. The current general approach is to 
minimize long-term immunosuppression. Various withdrawal 
protocols target individual components of the immunosup-
pressive regimen (e.g., corticosteroids, calcineurin inhibitors) 
in an attempt to decrease serious complications of immuno-
suppression; namely, infection, malignancy, and renal 
dysfunction. 
OVERVIEW OF TRANSPLANTATION 
IMMUNOBIOLOGY 
Antigen specificity is determined by an antigen-binding unit 
on the surface of the T cell called the T-cell receptor (TCR). 
The specificity and diversity of the TCR binding site result 
from variations in its amino acid composition among different 
T cells. The gene sequence coding for the TCR rearranges 
during development in the thymus, such that each T cell has 
a different TCR binding specificity. The result is a complex 
system that enables lymphocytes to discriminate between 
"self" and "nonself" or foreign antigen. 
Once inside tissues or the circulation of the body, foreign 
antigen is presented to the lymphocytes by antigen-presenting 
cells (APCs), epitomized by dendritic cells. APCs phagocytose 
foreign proteins and cleave them enzymatically into small 
peptides that are S to 12 amino acids in length. These peptides 
are loaded onto a class of specialized carrier molecules, known 
as major histocompatibility complex (MHC) molecules. 
The MHC molecule carries the peptide fragment t 
surface, where it is displayed to T cells in the host a 
organs. Thus, there are three essential requirements 
adaptive immune response known as rejection: (1) th 
ence of an antigen fragment or protein (a ligand) at.~ 
surface of the APC, (2) a receptor fit for the liga de 
(3) the activation of T cells. n , and 
The migration pattern of the antigen also is a .. 
factor. The only mobile antigen in organ transpla c~~ca] 
consists of passenger leukocytes of bone marrow ori: :n 
are present in the graft and that migrate prompt:; t 
preferentially to host lymphoid organs.9- 11 These orga and 
. d h . 1 h·d 11 . ns or or~anlZe .eterotoplC ymp 01 co ectlOns . provide the 
umque archItectural structure and cellular mIlieu whe . 
factors that are necessary for progression from an imm:~~ 
genic environment to a tolerogenic environment are preseo t 
in abundance. These factors include cytokines, other mOln. 
cuIes, cell-cell proximity, and homing mechanisms th:t 
ensure an efficient response to the antigen. 12 In the lymphoid 
organs, dendritic cells and other APCs that have captured 
and processed the antigen present the peptide fragment of 
the antigen to antigen-specific TCRs in the context of their c, 
upregulated host MHC peptide. j:'C 
The efferent (effector) phase begins with the secretion 0(;" 
interleukin-2 (IL-2, or T-cell growth factor) and interferon.a . 
(IFN -a) by activated lymphocytes. The antigen-specific 
immune activation and clonal expansion is aborted unless 
there is upregulation by the APCs of "accessory" cell-bound 
(costimulatory) molecules that sustain accelerated production 
of IL-2 and foster the secretion of numerous other cytokines 
(e.g., IL-l, IL-6, IL-9, IL-I0, IFNs, tumor necrosis factor-a 
[TNF-aJ, TNF-P) and growth factors (granulocyte colony· 
stimulating factor [G-CSF] and granulocyte-macrophage 
colony-stimulating factor [GM-CSF])P The sequential nature 
of the response amplification has been obscured by use of 
the term "costimulatory" to describe the accessory molecules, 
implying that the afferent and early effector phases are 
simultaneous. 
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The TCR is a cell surface molecule that associates with 
"accessory" molecules, including CD3, and either CD4.or 
CDS. The TCR-CD3 complex interacts with the peptl~e 
fragment carried by the MHC molecule of the APe. This Corti, 
complex is stabilized by the CD4 or CDS molecul~ ~~ the . doses, 
T cell. This interaction produces the signal that Imtlates are a 
activation of the T cell, leading to proliferation of a T-cell proto 
clone that recognizes the particular antigen fragments of the Five g 
foreign protein. The basis for MHC-restricted antigen.recog- tion: I 
nition requires antigen presentation by APCs beanng an nisolc 
MHC molecule specific to the host. . Be 
11 I es IS activi Antigen-directed proliferation of T-ce con Th 
e catiol 
absolutely essential for an effective immune response. th t 
response is driven by a positive feedback loop. T cells a agent: 
lL 2 their recognize antigen make the potent growth factor .- iUth"'e--+- Pn 
simultaneously b.ecome respon~ive to 1L-2 by expres~iU~ate . itis IT 
1L-2 receptor. ThIS dual syntheSIS allows the cells.to stir ther Oral] 
their own proliferation, as well as the prolife.ratIon a :'0 per h If I 27c a.j 
T cells. Lymphocytes recirculate at a rate of 1 % to ·aliZed 3 hou 
hour, migrating through all tissues of the body. SpeC! diate With, 
cell surface "homing" molecules on T lympho~ytes ~ for COrtic 
attachment to targeted alien tissues, with a speCIal aVI ty lists f 
the endothelial cells of an allograft's vessels. 't ating Diolof 
During an ongoing immune response, proh erecha- Th 
T cells recruit many other cell types and immune II1 rivate for c, 
nisms into action. The cytokines can attract and aC 
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.••...... er leukocytes. For example, cytokines produced by CI?4-
"roth .. e helper T cells attract macrophages and CD8-beanng :~,posln\:ic lymphocytes into rejecting allografts. 14 These 
cyto~nes also trigger macrophage activation and CD8+ 
cyto phocyte cell maturation. The resulting multicellular ~,lym infiltration has traditionally been referred to as a 
uss~e d-type hypersensitivity response. Cytokines released by 
.dd ~~ T cells also are responsi~le .for the a~tivation of B ~ells 
h f thus, indirectly, for the maJonty of antIbody produ~tlOn. 
an kines also upregulate both MHC molecules on tIssues C~o dhesion molecules on endothelium. These events aid in ~ antry and accumulation of leukocytes. Finally, cytokines 
e e te distant organ responses, such as the hepatic acute 
actlva . . b h e response, productIOn of phagocytes III the one ·~::row, and the hypothalamic-pituitary axis, producing the 
'. signs of inflammation. 
Once the antigen is consumed or removed, the process 
d wnregulates. If antigen removal is incomplete, continuously 
o sitized ("memory") T cells remain and contribute to a ~~~onger secondary respon.se on rec~allenge :vith the same 
antigen. However, m some mstances, If the antIgen cannot be 
e!imlina·teCl, the immune response can become exhausted and 
'. cells deleted by mechanisms that are not fully understood 
include Fas ligand-mediated apoptosis. Exhaustion-
;.'deletion in the first weeks or months after transplantation is 
>never complete, but it can be maintained in a stable state by 
" numbers of persistent donor leukocytes. 
Molecular insights regarding IL-2 gene transcription 
the structure of the IL-2 receptor (IL-2R) have led to 
therapy. As molecular knowledge has 
"""Pct'CTo,t",r< have gained greater understanding 
many immunosuppressants. New strategies 
by this knowledge have resulted in attempts to develop 
immunosuppression. Virtually every known 
of the immune process can be targeted, and many new 
are now in various stages of evolution. 
are extensively used in brief courses, at high' 
the reversal of acute rejection episodes. These drugs 
used extensively in clinical immunosuppressive 
for both induction and maintenance phases. IS 
IUUC:()rt)Thrr."tPrnirlo are commonly used in transplanta-
prednisone, prednisolone, methylpred-
and dexamethasone. 
hydrocortisone has the greatest mineralocorticoid 
. per unit of glucocorticoid activity, its routine appli-
In transplantation is relatively limited. The other four 
?ave more glucocorticoid activity in proportion to 
mllleralocorticoid activity. 
has an oral bioavailability of about 80%, and 
in the liver to its active form, prednisolone. 
"'e' .• m.,,., •. ,_ has a bioavailability of 100%. The serum 
of both prednisone and methylprednisolone is 2 to 
. halfT~e oral bioavailability of dexamethasone is 61 %, 
. -hfe of 2 hoursY However, the clinical activity of 
2 (i.e., suppression of cytokine production) per-
4 .h?urs or longer. In other words, the half-life for 
a~IVlty is much longer than the circulating half-life. 
IS no universally accepted fixed dosing regimen 
Rather, the dose is often dictated by 
-.--.~~~~--.~.---------------
local protocoL A preoperative dose of 250 to 1000 mg of methyl-
prednisolone may be given, followed by 20 to 200 mg/day 
during the first week. Acute rejection may be treated with one 
to three large doses-2S0 to 1000 mg of methylprednisolone-
or by a regimen starting at 200 mg/day of oral prednisone 
and tapering to baseline maintenance doses over 3 to 6 days. 
There is evidence that doses lower than those traditionally 
used can be equally effective. In combination regimens, 
steroid doses often can be reduced to 5 or 10 mg/day or less 
and perhaps given every other day. 
Corticosteroids have broad effects on many cell types. These 
agents interfere with the production of IL-1 and IL-2, blocking 
the early steps ofT-cell activation. Other pharmacologic effects 
related to immune function include the following: 
1. Antagonism of inflammatory mechanisms by stabilization 
of leukocyte lysosomal membranes, reduction in capillary 
permeability, and inhibition of histamine release and the 
kinin and complement systems 
2. Drastic reduction of lymphocyte traffic and circulating 
immunoglobulin levels and reduction in the number of 
neutrophils and eosinophils 
3. Inhibition of leukocyte adhesion to endothelium 
Prednisone and prednisolone have much less mineralocor-
ticoid effect than the naturally occurring glucocorticoids do; 
however, sodium retention, edema, hypertension, potassium 
loss, and hypokalemic alkalosis can be seen with prolonged 
use of these drugs. Suppression of the pituitary-adrenal axis 
can be seen with all corticosteroids, but the magnitude of 
this effect varies among patients. Acute adrenal insufficiency 
can develop unexpectedly if patients are stressed, even as long 
as 12 months after steroids are withdrawn . 
The adverse effects of corticosteroids are numerous and 
cause considerable morbidity. An increased incidence of 
serious infections is well documented. Impaired fibroblast 
growth and collagen synthesis contribute to poor wound heal-
ing. Hence, surgical wounds and anastomoses are at increased 
risk for dehiscence, and gastrointestinal ulcers tend to heal 
slowly, leading to increased risks of perforation and rebleeding. 
Spontaneous ulceration of the gastrointestinal tract occurs 
in approximately 2% of patients taking steroids. Because signs 
of inflammation are suppressed, the diagnosis of intraabdom-
inal infection and peritonitis can be significantly delayed, 
sometimes with disastrous consequences. 
Steroids impair glucose tolerance, often dramatically. For 
patients receiving large doses of steroids, it often is best to 
use "sliding-scale" insulin regimens to ensure adequate control 
of blood sugar levels. Some patients require long-term therapy 
with oral hypoglycemic agents or insulin to maintain adequate 
glucose controL 
Central nervous system effects, such as euphoria and mood 
swings, are well known. These adverse effects are generally dose 
dependent and are seen most frequently early in the postoper-
ative period or with therapy for acute rejection episodes, when 
higher doses of steroids are used. Central nervous system 
effects are usually self-limited and do not require treatment. 
Long-term use of steroids can cause bone demineralization 
and lead to osteoporosis. Atherosclerosis may be accelerated. 
Prolonged administration of glucocorticoids is associated with 
an increased incidence of cataracts and elevated intraocular 
pressure (glaucoma). Soft-tissue and dermal changes (e.g., fat 
redistribution, skin atrophy, "moon face;' striae) produce 
the characteristic cushingoid appearance. 
n 
c 
z 
n 
» , 
c 
l/l 
m 
o 
-n 
~ 
~ 
c 
z 
o 
l/l 
C 
"tl 
"tl 
:%l 
m 
l/l 
l/l 
» 
z 
~ 
----~-,---
." 
I 
l> 
;;JJ 
s: 
8 
5 
G) 
-< 
l> 
Z 
o 
~ 
8 
5 
G) 
-< 
To minimize the development of adverse sequelae, most 
immunosuppressive protocols attempt to reduce the dose of 
steroids over time to physiologic levels (equivalent to 5 mg/day 
or less of prednisone). However, corticosteroid doses must be 
reduced carefully to minimize side effects while maintaining 
adequate immunosuppression to prevent acute rejection of 
the allograft. 
CYTOKINE INHIBITORS 
Before the introduction of cyclosporine, immunosuppression 
protocols relied heavily on corticosteroids and cytotoxic 
drugs. These regimens had the disadvantage of producing 
broad suppression of the immune and inflammatory cascades. 
Cyclosporine introduced a new era of immunosuppression, 
because it provided potent, relatively specific, and noncyto-
toxic suppression of T-cell activation. 
Cyclosporine 
Cyclosporine is a lipophilic cyclic polypeptide with 
11 amino acids and a molecular weight of 1202. On entering 
the T cell, cyclosporine binds to cyclophilin, a cytoplasmic 
immunophilin protein. The cyclosporine-cyclophilin complex 
inhibits the activity of calcineurin, which, in turn, inhibits 
transcription of several genes, including those transcribing 
IL-2, IL-3, IL-4, GM-CSF, IFN-y, and TNF-a. One key action 
that results from blockade of calcineurin is inhibition of sig-
naling via nuclear factor of activated T cells (NF-AT), which 
regulates activation of the IL-2 gene; this effect ultimately 
prevents the synthesis of IL-2.18 Inhibition of the synthesis 
of IL-2, a potent T-cell growth factor, is the crucial activity 
of cyclosporine. 
Cyclosporine is insoluble in water and therefore must be dis-
solved in an organic solvent. There currently exist two formula-
tions: cyclosporine (Sandimmune, Novartis Pharmaceuticals, 
East Hanover, NJ) and cyclosporine for micro emulsion 
(cyclosporine, modified; Neoral, Novartis Pharmaceuticals, 
and Gengraf, Abbott Laboratories, North Chicago, IL). 
The microemulsion formulation substantially increases 
cyclosporine absorption; the overall time to peak cyclosporine 
concentration is reduced, the peak concentration is higher, and 
the area under the curve (AUC) is increased. The lipophilicity 
of the conventional cyclosporine formulation is responsible 
for its variable bioavailability. 
Oral bioavailability is about 30%, but there is much indi-
vidual variability (range, 10% to 60%). Absorption in the 
small intestine decreases with bowel dysfunction or reduced 
bile tloW. 19 The volume of distribution of cyclosporine is 
large and variable. Cyclosporine is metabolized in the liver 
via cytochrome P450 (CYP) 3A4 enzymes. It also is a substrate 
for the p-glycoprotein efflux pump. The mean terminal half-
life with normal liver function is 19 hours. The microemulsion 
formulation of cyclosporine has superior pharmacokinetics, 
does not require bile excretion for its bioavailability, and is 
better dispersed and absorbed compared with conventional 
cyclosporine. The relative bioavailability of the micro emulsion 
formulation is approximately 60%.20 The total AUC is increased 
by 30% compared with the conventional formulation.21 
At least 17 cyclosporine metabolites have been identified, 
and at least a few of them are immunosuppressive, although 
considerably so less than the parent compound. The half-life 
increases with hepatic failure and is changed significantly by 
coadministration of a large number of other drugs that can 
increase or decrease serum levels by induction or competitive 
Increase 
Diltiazem 
Nicardipine 
Verapamil 
Fluconazole 
Itraconazole 
Ketoconazole 
Clarithromycin 
Erythromycin 
Methylprednisone (in large doses) 
Bromocriptine 
Danazol 
Protease inhibitors 
Rifampin 
Ca rbamazepine 
Phenobarbital 
Phenytoin 
Ticlopidine"~ 
NafCillin 
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inhibition of P450 (Table 192-1).22 For all these reasons, it is indue 
essential that levels be monitored regularly and dosage nitric 
adjusted accordingly. icityi! 
Monitoring of cyclosporine levels is not straightforward. cantir 
Different results are obtained when cyclosporine concentra- varies 
tions in blood or plasma are determined by radioim- Ne 
munoassay and by high-pressure liquid chromatography minOt 
(HPLC). Neither method is clearly superior, and there are no tions, 
universally accepted blood levels; target levels vary widely by eye 
from center to center. Desired levels in serum or plasma, as may 1 
measured by radioimmunoassay,23 are 150 to 250 ng/mL at causal 
the time of transplantation, tapering to 50 to 100 nglmL often. 
after 3 to 6 months. If the drug is measured in whole blood dram! 
by HPLC, desired levels are 100 to 300 ng/mL initially, tapering ness ir 
to 80 to 200 ng/mL. HypOJ 
Recent literature suggests that AUC values and peak be ris~ 
concentrations measured 2 hours after dosing (Cz) are more HY] 
sensitive predictors of cyclosporine effects and may be weeks 
better parameters to guide therapeutic monitoring of the ineidel 
microemulsion formulation of cyclosporine. Decreased popul, 
bioavailability of cyclosporine has been correlated with acute that IT 
rejection.24 The first 4 hours after administration of a dose of constr 
cyclosporine represents the period of greatest variability in perhaF 
cyclosporine absorption. z5 Limited sampling techniques, relaxat 
consisting of two to five blood samples drawn within the first vasoeo 
4 hours after cyclosporine administration, are used to deter- tion. H 
mine the AUe. AUC values greater than 4400 f.1g/Llhour cor- channt 
relate well with a low incidence of allograft rejection.24,26 One eye 
study compared the correlation between the trough concend effect 
tration, Cz, and the occurrence of rejection and conclude steroiC 
that trough concentrations lack predictive value; howalever, cyclosF 
acute rejection did not occur in patients with C2 v ufes In sen 
. e 0 a lactin, greater than 1200 f.1g/LP Because of the convemenc 
single blood sample compared with the multiple bl?od saJ11- cholest 
_;n<T-t:S----t- sis oftt 
pies necessary for AUC measurements, C2 . C C 
becoming a preferred way to adjust cyclosporine doS~gfirs~ a~;~:; 
levels should range between 1.5 and 2.0 f.1g/mL for ted to 
few months after transplantation and should be reduce tnanife Ivithin 
0.8 f.1g/mL after 6 to 12 months of therapy. 26,2S . . 4 to CYc!osr 
The typical daily intravenous dose of cyclos~onn: ~oscs> patient 
5 mg/kg. This amount can be given in two dJVlde oIlle adrnini 
each being delivered over 2 to 6 hours. Alternatively, S The 
f- I . . f . 24 hours. nephro pre er to use a sow, contmuous m uSJOn over tiIlles estirnat 
changeover to oral dosing usually requires a dose th~se orine nephro 
higher, or about 12 to 15 mg/kg/day. Oral cycl p 
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h uld be administered every 12 hours. After 1 to 2 weeks, the 
~ 0 age can be slowly tapered, once equilibration within body 
OSstores occurs. In many patients, the dose is tapered to as 
fat as 3 mg/kg/day by 6 months after transplantation. Liver 
IO~splant recipients who have a T tube, which diverts some 
~~e flow, require higher oral doses because of decreased 
~ orption. Pediatric patients eliminate cyclosporine faster ~:n adults do, and they require larger doses, typically about 
5 to 6 mg/kg/day intravenously and 14 to 18 mg/kg/day 
orally. Some pediatric patients require doses up to 50% to 
larger than adult doses. 
Several adverse effects can occur early after initiation of 
cvclosporine therapy. Acute nephr~toxicity and hypertension 
'e major problems. The mechamsms responsIble for these a~verse effects are controversial.29,30 Nephrotoxicity may be 
~e result of cyclosporine-induced afferent arteriolar vaso-
constriction that results, in part, from an imbalance between 
the production of prostaglandin E2, a vasodilator, and that of 
thromboxane A2, a vasoconstrictor.3!,32 Other possible factors 
include endothelin-1-induced vasoconstriction and impaired 
nitric oxide production.33 Cyclosporine- induced nephrotox-
icity is transient and reversible with a decrease in dosage or dis-
continuation of the drug.34 The incidence of nephrotoxicity 
varies from approximately 25% to 38%.35 
Neurotoxicity associated with cyclosporine ranges from 
minor toxicity, manifesting as tremors, to severe complica-
tions, such as seizures or encephalopathy.36 Tremors caused 
by cyclosporine are common (prevalence, 10% to 55%) and 
may improve over time without a change in therapy. The 
• causal association between seizures and encephalopathy 
often is not clear.36 Several reports have detailed a rare syn-
that is characterized by confusion and cortical blind-
'c. ness in both liver and bone marrow transplantation patients. 
· Hypomagnesemia and hypo cholesterolemia are believed to 
.•... be risk factors for cyclosporine-induced neurotoxicity.29 
. Hypertension occurs frequently and usually begins within 
· . weeks after commencement of cyclosporine therapy. The 
of hypertension varies widely in different patient 
1II~.])()pUlatl(ms ranging from 10% to 80%.35 It is hypothesized3? 
hypertension is caused by cyclosporine-induced vaso-
"v'''''U'_ll'L'lI in the renal or systemic circulation, or both, 
as a result of antagonism of endothelium-derived 
factors or increased synthesis of endothelin-1, a 
r. Hypertension responds to sodium restric-
Hypertension is best managed with diuretics or calcium 
blockers. 30 
e is diabetogenic, although analysis of this 
confounded by the frequent concomitant use of 
with cyclosporine. Other metabolic effects of 
include hypochloremic alkalosis and changes 
concentrations of potassium, magnesium, pro-
and testosterone. Hepatotoxicity, manifested by 
ft jaundice, is common,29 but intrahepatic cholesta-
Q en resolves if the dose of cyclosporine is reduced. 
tissue side effects of cyclosporine are common 
be distressing to the patient because of the cosmetic 
These changes include hirsutism (seen 
2 to 4 weeks in 20% to 45% of patients receiving 
), gingival hyperplasia (in 4% to 16% of 
and coarsening of facial features. 38 Long-term 
of cyclosporine is associated with irreversible 
-·VlO1",-;<.. The incidence of this serious side effect is 
15% to 40%.39 The pathologic lesion resembles 
VO\.Jt'r~.";~ 40 
Tacrolimus 
Tacrolimus (FK-506; Prograf, Fujisawa Healthcare, 
Deerfield, IL) is a macrolide antibiotic with immunosup-
pressive activity produced by the fungus Streptomyces 
tsukubaensis. It is approved by the u.s. Food and Drug 
Administration (FDA) for liver and kidney transplant recip· 
ients. It is also used extensively in small bowel, pancreas, 
heart, and lung transplantation. The molecular structure of 
tacrolimus is unrelated to that of cyclosporine, and the two 
drugs have different cytosolic binding sites.41 .42 Tacrolimus 
binds to the immunophilin called FK-binding protein-12 
(FKBP12).43 Like the cyclosporine-cyclophilin complex, the 
tacrolimus-FKBP 12 complex binds to and inhibits the activity 
of calcineurin. As is the case with cyclosporine, inhibition of 
calcineurin by tacrolimus blocks the transcription of several 
genes, including the genes transcribing IL-2, IL-3, IL-4, 
GM-CSF, IFN-y, and TNF-u. The effect of tacrolimus on 
TNF-~ expression differs from that induced by cyclosporine, 
Tacrolimus-mediated inhibition of TNF-~ expression may 
playa role in reducing chronic rejection,43 although no clinical 
difference has been noted between the two drugs. Like 
cyclosporine, inhibition of calcineurin disrupts signaling via 
NF-AT, ultimately inhibiting the synthesis of the potent 
T-cell growth factor, IL-2; this is the key pharmacologic effect 
of tacrolimus. The immunosuppressive effects of tacrolimus 
also may involve other pathways that activate T cells.44 
Tacrolimus is highly lipophilic and must be dissolved in 
an organic solvent. Oral bioavailability is highly variable and 
poor, reportedly ranging from 6% to 56%, with a mean of 
25%.45 The gastrointestinal absorption of tacrolimus, com-
pared with that of cyclosporine, is less dependent on bile 
flOW. 46 Tacrolimus is extensively bound to erythrocytes 
because of the high concentration of FKBP12 found in the 
red blood cells. Like cyclosporine, tacrolimus is metabolized 
in the liver via the cytochrome P450 enzyme system, primarily 
by CYP3A4, although other enzymes have been reported 
to be involved as well.47 Tacrolimus metabolism, like that of 
cyclosporine, can be significantly altered by liver dysfunction 
or coadministration of other drugs that induce or competi-
tively inhibit P450; these effects can decrease or increase cir-
culating levels of tacrolimus (see Table 192-1). Tacrolimus is 
a substrate for the p-glycoprotein efflux pump. The mean 
terminal half-life of tacrolimus is 12 hours. At least 
15 metabolites of tacrolimus have been identified.43 Some of 
these metabolites have as much as 10% of the immuno-
suppressive activity of the parent compoundY 
Therapeutic monitoring of circulating tacrolimus 
concentrations is essential for preventing toxicity while main-
taining adequate immunosuppression. Plasma and whole-
blood trough concentrations correlate with AUC as well as 
clinical outcomes and toxicities.48 Because of the extensive 
binding of tacrolimus to erythrocytes, whole-blood tacrolimus 
concentrations are 10 to 30 times higher than the correspon-
ding plasma concentrationsY The most commonly used 
tacrolimus assay is the microparticulate enzyme immunoas-
say, although HPLC and enzyme-linked immunosorbent 
assays are also readily available.49 The therapeutic range for 
tacrolimus levels in whole blood is 5 to 20 ng/mL. Plasma 
tacrolimus levels should be maintained between 0.5 and 
2 ng/mL. 
The typical intravenous dose of tacrolimus is 0.05 to 
0.1 mg/kg/day. The drug should be administered as a slow, 
continuous infusion over 24 hours. Oral doses are generally 
three to four times higher than intravenous doses and range 
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from 0.1 to 0.2 mg/kg/day, administered in two divided doses 
every 12 hours. Maintenance doses of tacrolimus range from 
0.0125 to 0.5 mg/kg/day due to variability among patients 
with respect to absorption of the drug and requirements 
for immunosuppressionY No decrease in tacrolimus dose is 
needed when the T tube is clamped after liver transplantation. 
Tacrolimus clearance is faster in pediatric patients; therefore, 
larger doses may be required in children compared with 
adultsY Pediatric intravenous doses range from 0.03 to 
0.05 mg/kg/day, and pediatric oral doses range from 0.15 to 
0.3 mg/kg/day in divided doses. 
Tacrolimus has a potential advantage over cyclosporine 
because of its ability to reverse ongoing acute rejection. 50-53 
Experience with tacrolimus was first gained when the drug was 
used as rescue therapy in liver and kidney transplantation. 54-56 
Today, tacrolimus is used as a primary immunosuppressive 
agent for all types of solid organ transplants. 
The toxicity profile for tacrolimus is similar to that of 
cyclosporine, perhaps because they have a similar mechanism 
of action (i.e., calcineurin inhibition). As experience has 
been gained with tacrolimus, it is clear that many of the toxic 
side effects are dose related and are best managed by reducing 
the dose. Acute nephrotoxicity induced by tacrolimus is dose 
related. The incidence is not clearly defined in the literature, 
but it is similar to that of cyclosporine and most likely results 
from afferent arteriolar vasoconstriction. Nephrotoxicity 
resolves after the dose of tacrolimus is reduced or the drug is 
discontinued. As with cyclosporine, irreversible renal injury 
can occur after prolonged therapy with tacrolimusY 
Neurotoxicity is the most commonly reported adverse 
effect of tacrolimus. The reported incidence ranges from 
3.6% to 32%.58 This side effect can range from mild toxicity, 
such as tremors, headaches, paresthesias and insomnia, to 
severe complications including encephalopathy, coma, 
seizures, and psychosis. Usually, neurotoxicity associated with 
tacrolimus responds to a reduction of the dose; however, 
idiosyncratic reactions may require discontinuation of 
the drug. 
The potential for tacrolimus to induce a diabetic state is 
similar to that for cyclosporine.59,60 Increased fasting glucose 
levels and the development of overt diabetes mellitus are 
associated with elevated tacrolimus concentrations (greater 
than 15 ng/mL) , acute rejection, and higher body mass 
index.6l Tacrolimus-induced diabetes mellitus is reversible,62 
Hyperkalemia and hypomagnesemia are commonly 
noted in patients receiving tacrolimus. Acute hyperkalemia 
can be managed with standard approaches, including 
administration of insulin and glucose and sodium bicarbonate 
or a cation exchange agent (sodium polystyrene sulfonate). 
Chronic hyperkalemia may require therapy with fludro-
cortisone acetate to increase renal potassium excretion. 
Hypomagnesemia often requires magnesium replacement to 
avoid complications. 
The incidences of hypertension and hyperlipidemia asso-
ciated with tacrolimus therapy appear to be lower than those 
reported with cyclosporine.63-66 This more favorable adverse 
effect profile has been reported to translate into a decrease 
in the number of cardiovascular complications in patients 
treated with tacrolimus compared with cyclosporine.66 
Tacrolimus is not associated with the connective tissue 
side effects seen with cyclosporine; therefore, cosmetic prob-
lems are not seen. Alopecia can be problematic for patients 
receiving tacrolimus, but this problem is reversible and usually 
does not require dosage adjustments.67 
CELL CYCLE INHIBITORS 
The precise mechanism of immunosuppression 
cytotoxic drugs is not known; however, the negaf 
these agents on the proliferation of lymphocytesl~e 
to inhibit the generation of antigen-specific T-ceUlsl .........••.• 
one might expect, an increased risk of malignancie~ o~es.As ... 
long-term use of these agents is a concern. WIth the . 
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Azathioprine ulocytes 
Azathioprine (AZA; Imuran, Prometheus Labo .. the de nc 
Gre~nville, NC): a thio analog of the ~u:ine adenine,r:~~s; For this 
punne metabohsm. The parent drug IS InactiVe but is ~ts cytes, wh 
converted to 6-mercaptopurine (6-MP) in red blo:~Pl y MPA als, 
and subsequently to 6-thioinosine monophosphate a c~lls may intI 
I . . 68 B h th d d ' punne leukocytl ana og, In VIVO. ot e e novo an the salvage th 
ways of purine synthesis are inhibited by azathl'opP~ - Myco 
nne administ 6-Thioguanine nucleotides interfere with DNA and RNA' in the lj 
synthesis, rendering cells unable to function properly and bioavaila 
allowing. strand ~re~ in chromosomes. Azathioprine is of MPA ( 
most toxIC to proliferatmg cells that are making new DNA istration. 
Azathioprine can be used in maintenance immunosuppre~_ levels cal 
sive regimens; it has no usefulness for the treatment of acute other m 
rejection episodes.69 The oral bioavailability of azathioprine is . Metaboli 
approximately 40%. Metabolism of 6-MP involves catabolism and rena 
by xanthine oxidase in the liver and gut to inactive metabolites mycophe 
that are excreted by the kidneys. The 6-thioguanine by the ki 
nucleotides have a very long tissue half-life (approximately which ha 
13 days), permitting azathioprine to be administered by The d, 
once-daily dosing. The inactive end metabolite is 6-thiouric in kidney 
acid, which is excreted by the kidneys. With congenital transplar 
deficiency of the enzyme, thiopurine methyltransferase, immunm 
(incidence, 1 in 300 patients), or with renal failure, accumu- daily dos! 
lation of 6-thioguanine nucleotides causes increased toxicity. Patients, 
The starting dose for azathioprine is 3 to 5 mg/kg once benefit fr 
daily. The drug can be given intravenously at half the dose four dosiJ 
for brief periods. The typical maintenance oral dosage after The n 
transplantation is 2 to 3 mg/kg daily. Tapering of the dose to remains ( 
1 to 2 mg/kg per day is often possible over time. In combi- HPLC an 
nation regimens, azathioprine can be reduced to as low as (EMIT).] 
0.25 to 0.5 mg/kg/day. centratioI 
Dose-limiting myelosuppression usually occurs 1 :0 concentra 
2 weeks into therapy. Pancytopenia and thrombocytope~la reacts wjj 
with megaloblastic anemia is the pattern usually seen. WhIte concentra 
blood cell counts lower than 3000 cells/mm3 warrant dose both total 
reduction or discontinuation of the drug. As with other mined by 
antiproliferative drugs, nausea, vomiting, and hair loss m~y predicted 
occur. Hepatic injury can occur in two patterns. One form :5 the risk 0 
reversible hepatitis. The other form is rare but serious hep~tJc MPA ratt 
veno-occlusive disease, which can cause irreversible li~: therapeut 
damage. Azathioprine therapy also has been assocl.·a_.t.e~d,,;w'Mlt\'-_--1I-MPA trol 
pancreatitis. Because of concerns about hep . ed 3.5 lhg/L 
and pancreatitis, some transplantation experts que.st!O~,71 ~he early 
the value of azathioprine for immunosuppressIOn. se IC10]).RO F 
Hypersensitivity to azathioprine has been reporte~ tOdcauiS appropria 
a variety of manifestations; diagnosis of these dlsor ers The m 
based largely on clinical findings. es ~lild effec 
Allopurinol inhibits xanthene oxidase, one of ~he e~~bY ~nd dyspe 
involved in degradation of azathioprine metabolItes, ~gly, arge bOWl 
increasing the toxicity of the parent comp~und. Acc~r old be nOt been , 
if therapy with allopurinol is indicated, thIS agent s a tain- gastrointe 
added cautiously to an immunosuppressive regImen C~:se of ~Ptoms 
ing azathioprine. If allopurinol must be used, the ' Pi\. Or in 
azathioprine should be reduced by more than 50%. daily to th 
cophenolate Mofetil. . ~Ycophenolate mofetil (MMF; CellCept, Roche Laboratories, 
Ytlev, NIl is a prodrug of mycophenolic acid (MPA). MPA 
NU c~mpetitively inhibits inosine monophosphate dehydro-
O::ase (IMPDH), a key enzyme that regulates the purine 
g cleotide de novo synthesis pathway,72 T and B lymphocytes 
Ou dependent on IMPDH and the de novo pathway for purine 
:thesis during proliferation. Other cell lines, including gran-
locytes, red blood cells, platelets and tissue cells, use both 
~e de novO and the s~lvage pathwa~s for purine synthesis,73 
For this reason, MPA IS more selective for T and B lympho-
....... --..utI.S. which results in a more favorable adverse effect profile. 
MPA also may induce apoptosis in activated T cells, and it 
may interfere with expression of adhesion molecules in 
leukocytes and lymphocyte recruitmentJ4 
Mycophenolate mofetil is rapidly absorbed after oral 
administration and undergoes rapid first-pass metabolism 
in the liver to MPA, the active form of the drug. The 
bioavailability of MPA is 94%.72 Maximum concentrations 
. ofMPA are reached approximately 1 hour after oral admin-
istration,75 MPA binds to plasma albumin, and free MPA 
levels can be altered by fluctuations in albumin levels or 
other medications that compete for albumin binding. 
Metabolism of MPA occurs by glucuronidation in the liver 
and renal tubular cells, primarily to an inactive compound, 
mycophenolic acid glucuronide (MPAG), which is eliminated 
by the kidneys72 and to a second acyl glucuronide (M-2), 
which has in vitro activity,76 
The dose of mycophenolate needed to prevent rejection 
in kidney and liver transplant recipients is 2 g/day. Cardiac 
transplant recipients generally require higher levels of 
inImunosuppression and should receive 3 g/day. The total 
daily dose should be administered over two dosing intervals. 
Patients who are unable to tolerate twice daily dosing may 
benefit from separation of the total daily dose into three or 
four dosing intervals. 
The need for therapeutic monitoring of MPA levels 
remains controversial. Currently, two assays are available: 
HPLC and an enzyme-multiplied immunoassay technique 
(EMIT). HPLC can measure both MPA and metabolite con-
centrations and is sensitive enough to measure free MPA 
concentrations,7? The active metabolite of MPA, M-2, cross-
reacts with the EMIT assay, resulting in higher measured 
concentrations. A correlation between acute rejection and 
~th total MPA AVC and trough MPA concentrations deter-
mmed by HPLC has been demonstrated,78 Acute rejection is 
~edi.cted better by trough levels than by the AVe. However, 
Me fisk of adverse effects correlates better with the dose of 
th PA rather than circulating MPA concentrationsJ9 The 
Merapeutlc range for total MPA AVC is 30 to 60 mg/h/L,78 
3:A tro~~h levels should be maintained between 1 and 
~ mg/L.· I Another monitoring strategy is measurement of 
ICe early peak concentration (30 minutes after oral dose 
a Jo]).sO,Further studies are necessary to determine the most 
P~opnate strategy for therapeutic monitoring of MPA. 
IrIiJdhe most common adverse effects are gastrointestinal. 
IIld deffects I.nclude nausea, vomiting, diarrhea, constipation, 
lar Yspepsla. Severe complications, including cholecystitis, 1Io~~ bowel perforation, and pan creatitis, are rare and have 
taslr ~en definitively related to treatment with MPA. Mild ~ OIntestinal effects usually are transient. Prolonged 
\\proms can be managed by either reducing the dose of 
, Or lncreasing the number of dosing intervals from twice 
to three or four times daily.81 
Hematologic adverse effects are rare and are manifested 
as bone marrow suppression. The most commonly reported 
features are leukopenia and anemia, but the side effect profile 
also can include thrombocytopenia and pancytopenia, The 
onset of myelosuppression typically occurs within the first 
6 months after starting MPA therapy and may be dose related. 
Resolution occurs within 1 week after stopping the drug in 
most cases,?2 
Infections are frequently cited as adverse effects of MPA, 
but they are a complication of immunosuppression in 
general. The reported incidence of opportunistic infections 
was increased in patients receiving MPA in addition to 
cyclosporine and prednisone compared with those receiving 
cyclosporine and prednisone alone81,83; however, no difference 
was reported when the MPA-containing regimen was com-
pared with cyclosporine, prednisone, and azathioprine.84 
Nephrotoxicity and hepatotoxicity have not been reported 
with MPA. 
MPA is effective maintenance therapy for prevention of 
acute rejection of solid organ allografts in combination with 
other immunosuppressive agents, such as corticosteroids 
and cyclosporine82-84 or tacrolimus.85 MPA has been used to 
treat acute rejection of renal transplants86 and, in refractory 
rejection, to reduce the use of antilymphocyte therapy.87 
In addition, MPA has been used as rescue therapy for acute 
and chronic rejection of cardiac transplants.88 Recent studies 
have shown promise in combining MPA with sirolimus to 
eliminate the need for calcineurin inhibitors, thereby reducing 
the potential for nephrotoxicity.89,9o 
Sirolimus 
Sirolimus (rapamycin; Rapa; Rapamune, Wyeth Laboratories, 
Philadelphia, PA) is a macrolide antibiotic that is struc-
turally related to tacrolimus. Like tacrolimus, it also binds to 
FKBPI2, but sirolimus does not inhibit calcineurin or block 
cytokine gene transcription in T cells; rather, it inhibits the 
mammalian targets of rapamycin (mTOR). When stimulated 
by 1L-2 and other growth factors, mTOR activates kinases 
that translate cytokine messenger RNA, which ultimately 
progresses the cell cycle from GI to the S phase. By blocking 
mTOR, sirolimus inhibits the cellular response to IL-2 and 
inhibits progression of the cell cycle, thereby prohibiting 
T-cell proliferation.91 
Sirolimus is insoluble in water and must be dissolved 
in an organic solvent. It has poor bioavailability (15%). 
Maximum concentrations are reached within 2 hours after 
oral administration. 92 Because of its high lipophilicity, 
sirolimus readily enters cells, producing a large volume of 
distribution. Sirolimus binds extensively to erythrocytes 
(95%) because of their high FKBP12 content; minimal binding 
occurs with other plasma proteins.93 Like cyclosporine and 
tacrolimus, sirolimus is metabolized primarily in the liver by 
CYP3A4. Sirolimus is also a substrate for the p-glycoprotein 
efflux pump. O-demethylation and hydroxylation produce 
several metabolites. The metabolites of sirolimus have less 
than 10% of the immunosuppressive activity of the parent 
compound and are excreted via the bile into feces. 91 
Hepatic metabolism by the CYP3A4 enzymes creates the 
potential for significant changes in the half-life of sirolimus 
if other drugs affecting these enzymes are also administered. 
These changes can decrease or increase serum levels by induc-
tion or competitive inhibition of P450. Many of the same 
drugs that alter cyclosporine and tacrolimus levels can also 
alter sirolimus levels (see Table 192-1). Coadministration of 
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sirolimus with cyclosporine significantly increases the AUC 
and trough concentrations for sirolimus. Likewise, sirolimus 
also significantly increases the AUC and trough concentra-
tions for cyclosporine. To minimize the interaction and 
potential toxicities of the two drugs, sirolimus administra-
tion should be separated from cyclosporine administration 
by 4 hours. 94 
Its long half-life of approximately 60 hours95 makes 
sirolimus suitable for once-daily dosing. The two pivotal 
trials that led to the FDA-approval of sirolimus capitalized 
on the interaction that occurs with coadministration of 
cyclosporine and sirolimus. These studies demonstrated a 
reduction of acute rejection episodes in kidney transplant 
recipients when sirolimus was given using either of two fixed 
dosing regimens: a 6-mg loading dose followed by 2 mg daily 
or a 15-mg loading dose followed by 5 mg daily.96,97 These 
results suggest that therapeutic drug monitoring is not nec-
essary. However, clinical experience indicates that sirolimus 
therapy is optimized when doses are based on blood con-
centrations, particularly if sirolimus is used in the absence of 
cyclosporine synergy.98 
Therapeutic monitoring of sirolimus should be based on 
whole-blood concentrations, because large amounts of the 
drug are sequestered in erythrocytes, resulting in undetectable 
concentrations in plasma.99 HPLC with mass spectroscopy 
and ultraviolet detection are the most commonly used 
methods to measure sirolimus concentrations. A correlation 
between the trough level and the AUC for sirolimus has been 
established.lOo,lol Furthermore, there is a strong correlation 
between the rate and severity of acute rejection and low 
trough levels, as well as between the occurrence of adverse 
effects and high trough levels. The therapeutic range is 5 to 
15 ng/mL.lOl A microparticle enzyme immunoassay has been 
developedl02 and may be beneficial for analyzing multiple 
samples with more rapid turnaround. lo3 Frequent monitor-
ing of sirolimus levels is not warranted because of the long 
half-life of the drug. Sirolimus levels should be evaluated 
5 to 7 days after initiation of therapy or a dose change, to 
allow sufficient time for drug levels to reach steady state. 100 
The adverse effect profIle of sirolimus is different from 
that of other immunosuppressants. Unlike cyclosporine and 
tacrolimus, sirolimus rarely causes nephrotoxicity or neuro-
toxicity. Dose-dependent myelosuppression can be seen after 
initiation of sirolimus therapy. Thrombocytopenia commonly 
manifests within the first 2 weeks of therapy but improves 
with continued treatment. Leukopenia and anemia may also 
manifest shortly after initiation of therapy, but they are 
transient.l03 Thrombocytopenia and leukopenia are related 
to sirolimus trough concentrations greater than 15 ng/mL.lOI 
Hyperlipidemia is commonly seen in patients receiving 
sirolimus; the findings are hypercholesterolemia and hyper-
triglyceridemia. This effect has been reported in virtually all 
clinical trials.9J Peak levels of total cholesterol and triglycerides 
are dose related and usually are reached within 3 months 
after initiation of sirolimus, but the levels decrease after 
1 year.103 Both changes are reversible with dose reduction or 
discontinuation.92 The cause of sirolimus-associated hyper-
lipidemia is thought to be overproduction of lipoproteins or 
inhibition of hepatic lipoprotein lipase, leading to decreased 
lipolysis. lo3 Use of antihyperlipidemic agents, such as the 
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitors, is etIective for treating hyperlipidemia 
in patients receiving sirolimus. Analysis of cholesterol values 
after 1 year of sirolimus therapy in the Framingham Model 
indicates that sirolimus should cause only a modest increase 
in the incidence of ischemic heart disease in kidney transplant 
recipients (2 to 3 new cases per 1000 persons per year).IOJ 
Therefore, treatment with sirolimus should have only a mini-
mal impact on the risk for cardiovascular disease. It has been 
proposed that the decreased incidence of hyperlipidemia 
associated with tacrolimus compared with cyclosporine may 
lessen the frequency and severity of hyperlipidemia in trans-
plant recipients who receive tacrolimus- and sirolimus-based 
immunosuppressive therapy.lo3 
Mouth ulcers have been reported with sirolimus; they 
appear to be more pronounced with the liquid formulation 
and may be dose related. Other adverse effects reported with 
sirolimus include elevated liver enzymes, lymphocele forma-
tion, hypertension, rash, acne, diarrhea, and arthralgia. 
Sirolimus is effective as maintenance therapy for the pre-
vention of acute rejection of solid organ allografts in combi-
nation with steroids and cyclosporine96,97 or tacrolimus. l04 It 
also is effective in steroid-withdrawal regimens 105 or to spare 
cyclosporine in an attempt to minimize nephrotoxicity asso-
ciated with this agent. 106,107 It is speculated that sirolimus 
may reduce the potential for chronic rejection by inhibiting 
growth factor-mediated cell proliferation and intimal 
hyperplasia associated with chronic rejection,103 but longer 
follow-up is necessary to prove this theory. 
BIOLOGIC AGENTS 
Antithymocyte Globulin 
Antilymphocyte antibodies such as antilymphocytic globulin 
(ALG) were first produced by immunization of animals against 
purified lymphocyte preparations, resulting in multispecific 
polyclonal antibodies. Antibodies that cross-reacted with other 
cellular molecules in blood were then removed by extensive 
adsorption to blood components. Because of variability among 
immunized animals, substantial amounts of ALG were pooled 
to produce a more homogeneous preparation. 
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Antibodies to surface molecules on lymphocytes interfere 
with lymphocyte function in the immune response by several 
possible mechanisms. Lymphocytes are removed from the 
circulation rapidly after treatment with antilymphocyte 
antibodies. In addition, lymphocytes are phenotypically and 
functionally altered. Thymocytes, unactivated lympho0'1;es, 
and T and B lymphoblasts are used to produce the equme 
polydonal antibody, antithymocyte globulin (ATG; ATG~, 
Pharmacia & Upjohn, Kalamazoo, MI). A newer ra~bl~ 
preparation, RATG (Thymoglobulin, SangStat MedIca 
Corporation, Fremont, CAl, is less immunogenic and may 
have other advantages over the equine preparation. B IY~ 
phocytes are targeted to a lesser extent with RATG than ~I 
. c tlOn- a1 
equine ATG,108 helping to some extent to preserve JUlec _ r 
induced antibody production. Furthermore, CD4+ Tt;:\ tt 
phocytes are the predominant target of RATG,109 an t 1, ____ -+_ 
agent has lesser effects on other leukocytes, compa~ed ~ r a 
equine ATG. RATG-induced lymphocytopenia perSIsts ~a-
much longer time than with former antilymph~cyte prit.rG 
tions. Surface molecules that serve as binding sItes for CP40, 
include the T-cell antigens, CD6, CDI6, CD18,.CD3~' nola! 
and CD58, among others. The result is inhibitIOn 0 cecytes, 
function of other cell lines, including monocytes, thyl11° 
natural killer cells, leukocytes, and dendritic cells. (10 to 
Equine ATG is administered in a single daily dOs: is 1 to 
15 mg/kg). The dose of RATG, which is more pote~ ~ aCU~ 
1.5 mg/kg given as a single daily dose. TherapY 0 
11 
ir 
tl 
rejection usually is continu~d f~r 7 to. 14 days. Induction 
therapy with polyclonal antlbodles typlCally uses the same 
doses for 5 to 10 days of therapy. Polyclonal preparatlOns 
ause a high incidence of febrile reactions with the first few ~oses. Antihistamines (usually diphenhydramine~ 50 m?), 
antipyretics (i.e., acetaminophen, 650 mg), and cortlcosterOlds 
are given as premedications. 
Because of the lack of specificity of polyclonal antibodies, 
therapeutic drug monitoring generally is not useful. In addi-
tion, fixed weight-based dosing regimens reduce the need for 
drug concentration monitoring. Some advocate monitoring 
number of CD3+ lymphocytes with flow cytometry as a 
gauge of immunosuppressive effect. 
The effects of ATG on other cell types is the basis for 
adverse effects associated with these preparations. The most 
troublesome adverse effect is myelosuppression, manifested 
by leukopenia, anemia, and thrombocytopenia. These effects 
are dose related and can be managed by decreasing the dose 
or discontinuing the drug. 
As described previously, the first few doses of ATG prepa-
rations are often accompanied by fever, which can be ame-
liorated with the use of appropriate premedications. Other 
adverse effects include anaphylactic reactions, hypotension, 
urticaria, and serum sickness, particularly with equine ATG. 
After approval of RATG, use of equine ATG declined consid-
erably because of the better side effect profile of RATG and 
its increased efficacy in reducing acute rejection 110 and 
preventing rejection as part of induction therapy.lll 
The efficacy of ATGs in reversing solid organ allograft 
rejection has been well established. ATGs are frequently 
reserved for steroid-resistant allograft rejections. Prospective, 
controlled studies have demonstrated equal or superior effi-
cacy for both equine and rabbit ATG in preventing rejection 
as induction therapy, compared with OKT3. 112,113 High doses 
of RATG are also being used in T cell-depleting regimens to 
induce tolerance and to allow for monotherapy after transplan-
tation with subsequent weaning of inlmunosuppression.114 
Anti-CD3 Monoclonal Antibody 
Efforts to increase the potency and decrease the variability of 
ALGs led to development of single-specificity monoclonal 
antibodies. The first of these products was muromonab CD3 
(OKT3; Orthoclone OKT3, OrthoBiotech Products, LP, 
Raritan, NJ). OKT3 is a purified murine-derived monoclonal 
antibody directed at the £ chain of the CD3 receptor,1l5 which 
lsfound on all mature human T cells. ll6 After administration, 
OKT3 binds to the CD3 receptor, opsonizing the cells and 
promoting their rapid removal from the circulation. I 16,1 17 
Elimination of OKT3 occurs in two phases and is princi-
pally linked to T-cell binding. The first phase is elimination 
~sociated with rapid removal of the T cells bound to OKT3. 
tbhe second, slower phase occurs days after initiation of 
erapy. The overall half-life for fue agent is 18 hours. ll7 
10 Dosing for OKT3 uses a fixed regimen of 5 mg/day for 
. dto 14 days for treatment of acute rejection. Prophylactic 
1Il u . th Ction regimens use the same dose for 7 to 10 days. After 
~ first one or two doses, pro inflammatory cytokines are 
re e~s~d by opsonized lymphocytes, leading to clinical findings ~lIlis~ent of severe sepsis.117 This first-dose effect frequently 
diaassOclated with fever, chills, tachycardia, nausea, vomiting, 
rrhea, bronchospasm, pulmonary edema, and elevation 
. depression of blood pressure. These effects can be ame-
if the patient is pretreated wifu a I-g intravenous 
of methylprednisolone 15 to 60 minutes before 
OKT3 infusion. liB Premedication often also includes antihist-
amines, diphenhydramine, and acetaminophen. Anaphylaxis 
occurs in fewer than 1 % of patients; nonetheless, a skin test or 
test dose is recommended before OKT3 therapy is initiated. 
The murine nature of the drug leads to anti-mouse 
immunoglobulin antibody formation. Individuals vary in 
the amount of endogenous antibody (directed against the 
mouse antibody) they form. This antibody production can 
be decreased by continuing other immunosuppressive treat-
ments during monoclonal antibody administration. Human 
antimurine OKT3 antibodies usually peak after 1 to 2 weeks 
of therapy and can decrease the efficacy of future courses of 
therapy,ll7 Repeat treatment with OKT3 is still successful in 
many cases, if larger doses of antibody are used for subsequent 
courses. Patients who produce very high antibody titers, 
probably about 5% to 20% of those receiving OKT3, fail to 
respond to subsequent doses of the drug even when the dose 
is increased. Some advocate monitoring of CD3+ T-cell 
counts with flow cytometry for patients receiving OKT3. If 
CD3+ cells reach 10%, it is recommended either that the dose 
of OKT3 be increased (to as much as 15 mg/day) or thattreat-
ment be discontinued. Others suggest monitoring anti-OKT3 
antibody titers. 
As described previously, OKT3 therapy produces a first-
dose response that manifests within 45 to 60 minutes and 
must be managed with premedication. Because of the risk of 
severe pulmonary edema, fluid status should be evaluated if 
patients weigh more than 2% more than their usual body 
weight, and diuresis should be considered before proceeding 
with OKT3 fuerapy. 
Septic meningitis also has been described as an early 
complication of OKT3 therapy, manifesting 2 to 7 days 
after initiation of OKT3. The common symptoms are fever, 
headache, and photophobia. The phenomenon appears to be 
self-limited and may be related to the release of cytokines 
early after OKT3 administration. 
The potent suppression of T-lymphocyte populations is 
associated with an increased incidence of viral infections 
and lymphoproliferative disorders. It is not clear whether 
antibody therapy is worse in this regard than other approaches 
for achieving immunosuppression. Some evidence suggests 
that problems arise because antibodies are used for too long 
a time or too late in the course of resistant rejection, when 
the immunosuppression burden is already high. 
The efficacy of OKT3 for treatment of acute rejection and 
induction strategies is well documented. However, OKT3 
use has declined with the availability of better-tolerated 
antithymocyte preparations (i.e., RATG) that do not induce 
antibody production against the drug. OKT3 is often 
reserved as therapy for acute rejection that is resistant to 
steroids or other antilymphocyte preparations. 
Anti-lnterleukin-2 Receptor 
Monoclonal Antibodies 
T-cell activation is characterized by the expression of 1L-2 and 
high-affinity IL-2R by T cells. 1L-2 exerts its effects on 
T lymphocytes by binding to the IL-2R. By binding to the a 
subunit of the 1L-2R on activated T cells, anti-IL-2R antibod-
ies inhibit 1L-2-mediated T-cell activation and proliferation. 
Two anti-1L-2R monoclonal antibodies are currentlv available, 
daclizumab (Zenapax, Hoffman-LaRoche, Nutley, NJ) and 
basiliximab (Simulect, Novartis Pharmaceuticals). The impor-
tant differences between the two drugs relate to the structure 
of the antibodies and the dosing strategies for each. 
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Daclizumab is a unique hybrid monoclonal antibody in 
which the variable region (binding site for the IL-2R) is 
murine but the remainder of the immunoglobulin molecule 
is human (immunoglobulin GI ). Only 10% of the hyb.rid 
molecule is of murine origin. As a result, antibody formatIOn 
directed against the drug is decreased (e.g., in comparison 
with OKT3) and half-life is prolonged. Basiliximab i~ a 
chimeric anti-IL-2R antibody with a mechanism of actIOn 
that is the same as daclizumab. In this monoclonal antibody, 
murine immunoglobulin amino acid sequences represent an 
even smaller fraction of the protein than is case for 
daclizumab. 
Dosing strategies for anti-IL-2R monoclonal antibodies 
begin with administration of the first dose, before trans-
plantation. A dose of 1 mg/kg of daclizumab is administered 
intravenously, and this dose is repeated every 14 days for a 
total of five doses. Newer dosing strategies use higher doses 
(2 mg/kg), or abbreviated schedules of two or three total 
doses, or both.1l9 A 20 mg/kg dose of basiliximab is admin-
istered intravenously before transplantation, and this dose is 
repeated once more on day 4. 
Anti-IL-2R monoclonal antibodies are effective in pre-
venting acute rejection after transplantation. However, these 
agents are ineffective for reversing acute cellular rejection. 
Both drugs are well tolerated, with no differences in adverse 
effects reported in clinical trials between the drugs and 
placebo. Daclizumab and basiliximab have the reported ben-
eficial effects of reducing delayed graft function and delaying 
calcineurin inhibitor use (to decrease nephrotoxicity).I20,121 
Anti-CDS2 Monoclonal Antibody 
CD52 is a surface marker found on mature T and 
B lymphocytes. It also is found to varying degrees on mono-
cytes, macro phages, granulocytes, and natural killer cells. 
Alemtuzumab (Campath, ILEX Pharmaceuticals, LP, San 
Antonio, TX) is a humanized monoclonal antibody directed 
at the CD52 antigen that causes complete lympholysis, 
resulting in significant T-cell depletion. The early experience 
with alemtuzumab suggest that lower degrees of immuno-
suppression are needed after T-cell depletion following alem-
tuzumab infusion. Reports indicate that only single-drug 
therapy, usually with a calcineurin inhibitor (cyclosporine or 
tacrolimus) or sirolimus, is necessary after patients receive 
induction therapy with alemtuzumab.l22-124 Alemtuzumab 
also has been successfully used to treat acute rejection 
episodes. 125,126 
The dose of alemtuzumab administered in transplantation 
is 30 mg intravenously. Significant adverse effects are noted 
with administration of alemtuzumab, notably rigors, 
hypotension, fever, shortness of breath, bronchospasms, and 
chills. Premedication with diphenhydramine, acetaminophen, 
and corticosteroids is required before alemtuzumab adminis-
tration to minimize the infusion-related effects. Other adverse 
effects noted after alemtuzumab therapy include neutropenia, 
anemia, thrombocytopenia, and pancytopenia. 
IMMUNOSUPPRESSIVE AGENTS 
IN CLINICAL DEVELOPMENT 
Everolimus 
Everolimus (SDZ-RAD; Certican, Novartis Pharma AG, Basel, 
Switzerland) is an inhibitor of mTOR that is structurally sim-
ilar to sirolimus and is currently approved for use in Europe. 
Everolimus produces the same inhibition of cell cycle 
progression and ultimate inhibition of T-cell prore . 
D · f l' . lteratJo osmg or evero lmus IS 3 mg daily. The half-\'f n. 
everolimus is 16 to 19 hours, which is shorter than the h II~ .of 
of sirolimus.127 The adverse effects of everolimus are ~ -!lie 
to those reported for sirolimus and include hype shlmlilar 
I . h . 1 'd . rc 0 es tero emla, ypertng ycen emla, and hematologic ff -
such as thrombocytopenia and anemia. e eets 
Mycophenolate Sodium 
Mycophenolate sodium (Myfortic, Novartis Pharma AG) . 
. d fi l' f h' IS an entenc-coate ormu atlon 0 t e sodIUm salt of mycoph 
I· 'd h' I eno-lC aC.l t a~ IS current y approved for use in Europe. The 
entenc coatmg of mycophenolate sodium helps to mini . 
th .. 1 'd ffi mlze e gastromtestma SI e e ects that are associated 'th 
mycophenolate mofetil. Once in the small intes;1 
mycophenolic acid is released directly in the gastrointest~nel' 
C b . h' lila tract lor a sorptIOn. T e Immunosuppressive activity f 
mycophenolate sodium is identical to that of mycophenol? 
acid, the activated form of mycophenolate mofetil. The do~~ 
of mycophenolate sodium is 1.44 g/day, which is equivalent 
to 2 g/day of mycophenolate mofetil. 
Leflunomide 
Leflun.omide (Avara, Aventis Pharmaceuticals, Kansas City, 
MO) IS converted to an active metabolite, A77,l726. The 
latter compound inhibits de novo pyrimidine synthesis in 
T and B lymphocytes by inhibiting tyrosine kinase activity of 
the TCR or cytokine receptors. It is currently marketed as a 
treatmen~ fo: r~eumatoi~ arthritis. One study investigating 
leflunomlde m liver and kidney transplant recipients admin-
istere? a loading dose of 200 mg/day for 7 days, followed by 
a mamtenance dose of 40 to 60 mg/day. Concentrations 
greater than 50 Ilg/mL allowed for lower doses of prednisone 
and calcineurin inhibitor, whereas concentrations of less 
than 80 Ilg/mL were associated with fewer adverse effects. 
Adverse effects included skin rash, anemia, and elevated liver 
e.nzymes. 128 Leflunomide was effective in reducing acute rejec-
tion and may show promise in reversing chronic rejection. 129 
FTY-720 
FTY-720 is a novel immunosuppressant that does not affect 
T-cell activation but alters lymphocyte trafficking by altering 
the expression or function of adhesion molecules. The effect 
of treatment with this agent is the sequestration of T cells in 
secondary lymphoid organs (i.e., not in the allograft), produc-
ing peripheral lymphopenia. 130 FTY-720 is being investigated 
for the treatment and prevention of both acute and chronic 
rejection. 
Mizoribine 
Mizoribine is an imidazole nucleoside antibiotic that under-
goes phosphorylation to inhibit both IMPDH and guanosine 
5-monophosphate synthetase during purine synthesis. III 
The result is inhibition of RNA and DNA synthesis and con-
sequent inhibition of both humoral and cellular immune 
responses. Limited clinical trials using mizoribine in place of 
azathioprine and with cyclosporine and corticosteroids have 
shown decreased graft loss to chronic rejection in renal trans-
plant recipients. 132 Mizoribine has been used as a maintenance 
agent, in combination with cyclosporine and steroids, prima-
rily in renal transplantation patients. I33 The drug appears to 
have advantages over azathioprine, in particular less myelo~ 
toxicity and hepatotoxicity.134 Although it has not been C0:U 
pared in clinical trials, it is expected to have efficacy similar 
'1 
I 
I 
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to that of mycophenolate mofetil, because the two drugs 
have similar mechanisms of action. 135 
Mizoribine is administered once daily as an oral dose of 
50 to 300 mg/day. Peak blood levels are achieved 2 to 3 hours 
after an oral dose. The major elimination pathway of mizorib-
ine is renal (85% of the dose is excreted unchanged in the 
urine), and the half-life is 4 hours. 
Brequinar 
Brequinar is an antimetabolite with broad antineoplastic 
activity that has been tested in humans with cancer.136,137 It 
inhibits the de novo pathway of pyrimidine synthesis, blocking 
RNA and DNA synthesis. Dose-limiting toxicities are throm-
bocytopenia and a severe desquamative dermatitis. The 
antiproliferative effects of the drug appear to be mediated by 
depletion of the pyrimidine precursors needed for DNA and 
RNA synthesis. Brequinar is a potent immunosuppressant in 
a rat modeP38 and appears to act synergistically, at least 
in vitro, with cyclosporine and sirolimus,l39 
Anti-CD4 Antibody 
Antibodies targeted against the CD4 receptor prevent the ini-
tiation of the immune response caused by presentation of 
MHC class II alloantigens. Selective disruption of the MHC 
class II-CD4 interaction can prolong allograft survival and 
induce tolerance in animal models. 140 These antibodies reduce 
synovial inflammation in rheumatoid arthritis and cause pro-
found and long-term immunosuppression. 141 Use of anti-
CD4 in conjunction with cytotoxic T lymphocyte-associated 
antigen 4 immunoglobulin (CTLA4-Ig) has been shown to 
prolong the survival of hamster liver xenografts in rats.142 Use 
of murine OKT4 in cadaveric renal transplantation has not 
shown promise.143 A human anti-mouse antibody (HAMA) 
response of more than 3 times the pretreatment level was 
observed in 84% of patients. An open-label pilot trial of 
murine OKT4A in humans produced mixed results.144 The 
dose used in the study produced only partial CD4 saturation 
in all patients and was inadequate to reduce rejection. 
However, no HAMA response was observed. Other human-
ized anti-CD4 monoclonal antibodies are being evaluated.2,144 
Anti-CD4S Antibody 
The CD45 epitope plays a role in the regulation ofT-cell acti-
vation. The CD45RB monoclonal antibody has been shown 
to effectively prevent allograft rejection in animal models and 
may have some applicability in humans in the future. 
Anti-CD40-Ligand and Anti-CD40 Antibody 
CD40 is a costimulatory molecule for MHC class II alloanti-
gens that is present in large amounts on mature dendritic 
cells. Costimulation is necessary for T-cell sensitization and 
~ctivation. Use of antibodies to prevent co stimulation may 
Induce tolerance by blocking activation of the T cell. In 
animal models, anti-CD40 or anti-CD40-ligand monoclonal 
antibodies have been shown to prevent and even reverse acute 
aUograft rejection, leading to prolonged graft survival without 
the need for chronic maintenance immunosuppressionl 45,146 
and to delayed onset of chronic rejection. 147 Other studies have 
~emonstrated the tolerogenic potential of anti-CD40-ligand 
III animal models. 148 
~Ilti-Leukocyte Function-Associated 
I\lltigen_l 
.·.leukocyte function-associated antigen-l (LFA-l) plays an 
role in adhesion of leukocytes to endothelial cells 
and to a variety of targets on T cells during the immune 
response. The immunosuppressive effect of anti-LFA-l (anti-
CD lla, anti-CD 18) monoclonal antibody (odulimomab) was 
similar to that of RATG as induction therapy in renal 
allograft recipients. 149 Fewer patients required dialysis in the 
anti-LFA-l monoclonal antibody group, possibly due to 
prevention of endothelial cell activation and the consequent 
protection of the allograft from ischemic damage. This same 
effect of protection from renal ischemia has been confirmed 
in animal models. ISO The combination of anti-intracellular 
. adhesion molecule-l (ICAM-I) antibody (enlimonab) and 
anti-LFA-l monoclonal antibody has been shown to induce 
tolerance to murine cardiac allografts. 1SI ,152 
Anti-CTLA4-lg 
CTLA4-Ig is a chimeric fusion protein that blocks the 
B7-CD28/CTLA4 pathway and thereby inhibits T-cell activa-
tion and IL-2 production. Development of chronic renal allo-
graft rejection is prevented by CTLA4-Ig in animal models. 1s3 
Current studies are investigating the use of this molecule with 
other costimulatory modulators, such as anti-CD40 ligandl47 
and anti-LFA-l,154 to induce tolerance in animal models. 
Anti-Intracellular Adhesion Molecule-l 
ICAM-l is an immunoglobulin-like molecule that aids 
adhesion and migration of leukocytes in the vessels and also 
acts as a costimulatory molecule for T-cell activation. Use of 
anti-ICAM-l monoclonal antibody (enlimomab) has not 
shown promise in reducing the incidence of acute rejection 
or delayed graft function in renal transplants. ISS However, 
anti-ICAM-l in combination with anti-LFA-l produced 
tolerance in animal models.151.152 
FUTURE DIRECTIONS 
The number of patients awaiting solid organ transplantation 
continues to grow each year. However, the number of organs 
available for donation shows very little change from year to 
year. Increased organ donation awareness among the public 
and increased use of organs from living donors have con-
tributed to small annual increases in the number of organs 
available for transplantation, but the number still falls short 
of meeting the needs of the more than 80,000 candidates 
waiting for solid-organ transplants. Other strategies must be 
explored to try to meet the demand for organ transplantation. 
Greater understanding of the way the immune system 
functions with respect to chronic allograft acceptance is vital 
to increasing the survival of transplanted allografts. 
Complete allograft acceptance without immunosuppressive 
therapy' would eliminate the occurrence of long-term sequelae 
of immunosuppression, such as malignancies and opportunis-
tic infections. Chimerism, a principle that is becoming better 
understood by transplantation immunologists, allows the 
donor and recipient leukocytes to stably coexist. Chimerism 
is essential for complete allograft acceptance with or without 
immunosuppression. 
The principles of allograft tolerance build on the concept 
of chimerism in that the interaction between donor and 
recipient leukocytes allows for low-level activation of both 
populations, resulting in exhaustion of each species.9,156,157 
Tolerance can be induced with the use of T-cell-depleting 
regimens, followed by low doses of immunosuppressive 
medications. 1l4 Current research includes investigation of 
other means of modulating the immune response to induce 
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tolerance, including modulation of adhesion and costimula-
tion pathways. 
A better understanding of tolerance induction with 
immunosuppressive regimens will playa key role in permitting 
successful xenotransplantation. Use of xenoallografts can 
greatly increase the number of donor organs available for 
transplantation to help match the demand. 
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